We are live on ! Find out more
CYTH

Cyclo Therapeutics, Inc. Common Stock
CYTH

Delisted

CYTH was delisted on the 25th of March, 2025.

Back to rankings

15 hedge funds and large institutions have $1.83M invested in Cyclo Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

138% more capital invested

Capital invested by funds: $769K → $1.83M (+$1.06M)

25% more funds holding

Funds holding: 12 → 15 (+3)

Holders
15
Holders Change
+3
Holders Change %
+25%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$1.54M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$6.51K
3
UBS Group
UBS Group
Switzerland
+$4.64K
4
PGAM
Princeton Global Asset Management
New Jersey
+$496
5
Wells Fargo
Wells Fargo
California
+$413

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$94K

CYTH Hedge Fund Activity: Q4 2022 in Review

15 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q4 2022, worth a combined $1.83M — up 138% from $769K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CYTH positions and 1 closed out — a net gain of 3 holders — while 4 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $1.54M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $94K sold.

  • 15 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q4 2022, up from 12 in Q3 2022.
  • Funds reported $1.83M of Cyclo Therapeutics, Inc. Common Stock stock for Q4 2022, up 138% quarter-over-quarter.
  • 4 funds opened new Cyclo Therapeutics, Inc. Common Stock positions in Q4 2022 and 1 closed out, a net change of +3 holders.
  • The largest Cyclo Therapeutics, Inc. Common Stock buyer in Q4 2022 was Armistice Capital, an estimated $1.54M added.
  • The largest Cyclo Therapeutics, Inc. Common Stock seller in Q4 2022 was Renaissance Technologies, an estimated $94K sold.

Based on aggregated 13F filings for Q4 2022.